{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:14:21Z","timestamp":1762607661985,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004008","name":"Istituto Superiore di Sanit\u00e0","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004008","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Biotechnol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Lymphocyte-activation gene (LAG)3 is a 498 aa transmembrane type I protein acting as an immune inhibitory receptor. It is expressed on activated lymphocytes, natural killer cells and plasmacytoid dendritic cells. In activated lymphocytes, LAG3 expression is involved in negative control of cell activation\/proliferation to ensure modulation and control of immune responses. In view of its deregulated expression in tumor-infiltrating lymphocytes, LAG3, together with the additional immune checkpoint inhibitors CTLA4 and PD1, is considered a major target in order to reverse the immunosuppression typically mounting in oncologic diseases. Since many patients still fail to respond to current immune checkpoints-based therapies, the identification of new effective immune inhibitors is a priority in the ongoing fight against cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified a novel human single-chain variable fragment (scFv) Ab against a conformational epitope of LAG3 by in vitro phage display technology using the recombinant antigen as a bait. This scFv (referred to as F7) was characterized in terms of binding specificity to both recombinant antigen and human LAG3-expressing cells. It was then rebuilt into an IgG format pre-optimized for clinical usage, and the resulting bivalent construct was shown to preserve its ability to bind LAG3 on human cells.<\/jats:p><jats:p>Next, we analyzed the activity of the anti-LAG3 scFvF7 using two different antigen-specific CD8<jats:sup>+<\/jats:sup>T lymphocyte clones as target cells. We proved that the reconstituted anti-LAG3 F7 Ab efficiently binds the cell membrane of both cell clones after peptide-activation. Still more significantly, we observed a striking increase in the peptide-dependent cell activation upon Ab treatment as measured in terms of IFN-\u03b3 release by both ELISA and ELISPOT assays.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Overall, the biotechnological strategy described herein represents a guiding development model for the search of novel useful immune checkpoint inhibitors. In addition, our functional data propose a novel candidate reagent for consideration as a cancer treatment.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12896-019-0559-x","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T14:59:24Z","timestamp":1571324364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Development of a novel human phage display-derived anti-LAG3 scFv antibody targeting CD8+ T lymphocyte exhaustion"],"prefix":"10.1186","volume":"19","author":[{"given":"Alessandro","family":"Ascione","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Arenaccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Mallano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Flego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara","family":"Gellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Andreotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Fenwick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Pantaleo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Vella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Federico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,17]]},"reference":[{"issue":"1","key":"559_CR1","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/imr.12519","volume":"276","author":"LP Andrews","year":"2017","unstructured":"Andrews LP, Marciscano AE, Drake CG, Vignali DA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017;276(1):80\u201396.","journal-title":"Immunol Rev"},{"issue":"5","key":"559_CR2","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1084\/jem.171.5.1393","volume":"171","author":"F Triebel","year":"1990","unstructured":"Triebel F, Jitsukawa S, Baixeras E, Roman-Roman S, Genevee C, Viegas-Pequignot E, et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med. 1990;171(5):1393\u2013405.","journal-title":"J Exp Med"},{"issue":"11","key":"559_CR3","doi-asserted-by":"publisher","first-page":"5744","DOI":"10.1073\/pnas.94.11.5744","volume":"94","author":"B Huard","year":"1997","unstructured":"Huard B, Mastrangeli R, Prigent P, Bruniquel D, Donini S, El-Tayar N, et al. Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc Natl Acad Sci U S A. 1997;94(11):5744\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"559_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1084\/jem.176.2.327","volume":"176","author":"E Baixeras","year":"1992","unstructured":"Baixeras E, Huard B, Miossec C, Jitsukawa S, Martin M, Hercend T, et al. Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J Exp Med. 1992;176(2):327\u201337.","journal-title":"J Exp Med"},{"issue":"4","key":"559_CR5","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1158\/2326-6066.CIR-14-0150","volume":"3","author":"T Kouo","year":"2015","unstructured":"Kouo T, Huang L, Pucsek AB, Cao M, Solt S, Armstrong T, et al. Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of Plasmacytoid dendritic cells. Cancer Immunol Res. 2015;3(4):412\u201323.","journal-title":"Cancer Immunol Res"},{"issue":"18","key":"559_CR6","doi-asserted-by":"publisher","first-page":"18748","DOI":"10.1074\/jbc.M311227200","volume":"279","author":"W Liu","year":"2004","unstructured":"Liu W, Tang L, Zhang G, Wei H, Cui Y, Guo L, et al. Characterization of a novel C-type lectin-like gene, LSECtin: demonstration of carbohydrate binding and expression in sinusoidal endothelial cells of liver and lymph node. J Biol Chem. 2004;279(18):18748\u201358.","journal-title":"J Biol Chem"},{"issue":"6307","key":"559_CR7","doi-asserted-by":"publisher","first-page":"aah3374","DOI":"10.1126\/science.aah3374","volume":"353","author":"X. Mao","year":"2016","unstructured":"Mao X, Ou MT, Karuppagounder SS, Kam TI, Yin X, Xiong Y, et al. Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science. 2016;353(6307):aah3374.","journal-title":"Science"},{"issue":"1","key":"559_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1006\/abio.1996.0382","volume":"241","author":"R Mastrangeli","year":"1996","unstructured":"Mastrangeli R, Micangeli E, Donini S. Cloning of murine LAG-3 by magnetic bead bound homologous probes and PCR (gene-capture PCR). Anal Biochem. 1996;241(1):93\u2013102.","journal-title":"Anal Biochem"},{"issue":"10","key":"559_CR9","doi-asserted-by":"publisher","first-page":"5392","DOI":"10.4049\/jimmunol.169.10.5392","volume":"169","author":"CJ Workman","year":"2002","unstructured":"Workman CJ, Dugger KJ, Vignali DA. Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3. J Immunol. 2002;169(10):5392\u20135.","journal-title":"J Immunol"},{"issue":"9","key":"559_CR10","doi-asserted-by":"publisher","first-page":"5916","DOI":"10.4049\/jimmunol.180.9.5916","volume":"180","author":"B Liang","year":"2008","unstructured":"Liang B, Workman C, Lee J, Chew C, Dale BM, Colonna L, et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol. 2008;180(9):5916\u201326.","journal-title":"J Immunol"},{"issue":"9","key":"559_CR11","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.4049\/jimmunol.1002050","volume":"186","author":"P Hemon","year":"2011","unstructured":"Hemon P, Jean-Louis F, Ramgolam K, Brignone C, Viguier M, Bachelez H, et al. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol. 2011;186(9):5173\u201383.","journal-title":"J Immunol"},{"issue":"13","key":"559_CR12","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S0959-8049(01)00184-8","volume":"37","author":"CE Demeure","year":"2001","unstructured":"Demeure CE, Wolfers J, Martin-Garcia N, Gaulard P, Triebel F. T lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3\/MHC class II interactions in cell-cell contacts. Eur J Cancer. 2001;37(13):1709\u201318.","journal-title":"Eur J Cancer"},{"issue":"4","key":"559_CR13","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"559_CR14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nm.4321","volume":"23","author":"CH June","year":"2017","unstructured":"June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles' heel of cancer immunotherapy? Nat Med. 2017;23(5):540\u20137.","journal-title":"Nat Med"},{"issue":"5","key":"559_CR15","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989\u20131004.","journal-title":"Immunity"},{"issue":"5","key":"559_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nri2744","volume":"10","author":"LM Weiner","year":"2010","unstructured":"Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10(5):317\u201327.","journal-title":"Nat Rev Immunol"},{"key":"559_CR17","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3389\/fimmu.2015.00418","volume":"6","author":"I Le Mercier","year":"2015","unstructured":"Le Mercier I, Lines JL, Noelle RJ. Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators. Front Immunol. 2015;6:418.","journal-title":"Front Immunol"},{"issue":"6230","key":"559_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56\u201361.","journal-title":"Science"},{"key":"559_CR19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3389\/fonc.2018.00315","volume":"8","author":"HT Marshall","year":"2018","unstructured":"Marshall HT, Djamgoz MBA. Immuno-oncology: emerging targets and combination therapies. Front Oncol. 2018;8:315.","journal-title":"Front Oncol"},{"key":"559_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejca.2017.01.001","volume":"74","author":"WCM Dempke","year":"2017","unstructured":"Dempke WCM, Fenchel K, Uciechowski P, Dale SP. Second- and third-generation drugs for immuno-oncology treatment-the more the better? Eur J Cancer. 2017;74:55\u201372.","journal-title":"Eur J Cancer"},{"issue":"8","key":"559_CR21","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1172\/JCI120775","volume":"128","author":"A Popovic","year":"2018","unstructured":"Popovic A, Jaffee EM, Zaidi N. Emerging strategies for combination checkpoint modulators in cancer immunotherapy. J Clin Invest. 2018;128(8):3209\u201318.","journal-title":"J Clin Invest"},{"issue":"5","key":"559_CR22","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.copbio.2004.08.002","volume":"15","author":"DC Andersen","year":"2004","unstructured":"Andersen DC, Reilly DE. Production technologies for monoclonal antibodies and their fragments. Curr Opin Biotechnol. 2004;15(5):456\u201362.","journal-title":"Curr Opin Biotechnol"},{"issue":"4","key":"559_CR23","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.biotechadv.2009.04.004","volume":"27","author":"NE Weisser","year":"2009","unstructured":"Weisser NE, Hall JC. Applications of single-chain variable fragment antibodies in therapeutics and diagnostics. Biotechnol Adv. 2009;27(4):502\u201320.","journal-title":"Biotechnol Adv"},{"issue":"3","key":"559_CR24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.antiviral.2009.05.005","volume":"83","author":"A Ascione","year":"2009","unstructured":"Ascione A, Capecchi B, Campitelli L, Imperiale V, Flego M, Zamboni S, et al. Human monoclonal antibodies in single chain fragment variable format with potent neutralization activity against influenza virus H5N1. Antivir Res. 2009;83(3):238\u201344.","journal-title":"Antivir Res"},{"key":"559_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbiotec.2016.02.034","volume":"224","author":"M Pasello","year":"2016","unstructured":"Pasello M, Zamboni S, Mallano A, Flego M, Picci P, Cianfriglia M, et al. Design and construction of a new human naive single-chain fragment variable antibody library, IORISS1. J Biotechnol. 2016;224:1\u201311.","journal-title":"J Biotechnol"},{"issue":"10","key":"559_CR26","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/protein\/gzw040","volume":"29","author":"T Schlothauer","year":"2016","unstructured":"Schlothauer T, Herter S, Koller CF, Grau-Richards S, Steinhart V, Spick C, et al. Novel human IgG1 and IgG4 fc-engineered antibodies with completely abolished immune effector functions. Protein Eng Des Sel. 2016;29(10):457\u201366.","journal-title":"Protein Eng Des Sel"},{"key":"559_CR27","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ymeth.2018.09.003","volume":"154","author":"Katy L. Everett","year":"2019","unstructured":"Everett KL, Kraman M, Wollerton FPG, Zimarino C, Kmiecik K, Gaspar M, et al. Generation of Fcabs targeting human and murine LAG-3 as building blocks for novel bispecific antibody therapeutics. Methods. 2019;154:60-69. https:\/\/doi.org\/10.1016\/j.ymeth.2018.09.003 . Epub 2018 Sep 9","journal-title":"Methods"},{"issue":"7","key":"559_CR28","first-page":"1060","volume":"10","author":"E Sasso","year":"2018","unstructured":"Sasso E, D'Avino C, Passariello M, D'Alise AM, Siciliano D, Esposito ML, et al. Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies. mAbs. 2018;10(7):1060\u201372.","journal-title":"mAbs"},{"issue":"1","key":"559_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1365-2249.2009.03912.x","volume":"157","author":"KS Peggs","year":"2009","unstructured":"Peggs KS, Quezada SA, Allison JP. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol. 2009;157(1):9\u201319.","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"559_CR30","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019;20(3):326\u201336.","journal-title":"Nat Immunol"},{"issue":"1","key":"559_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nri3790","volume":"15","author":"LT Nguyen","year":"2015","unstructured":"Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3--potential mechanisms of action. Nat Rev Immunol. 2015;15(1):45\u201356.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"559_CR32","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1172\/JCI46102","volume":"121","author":"L Baitsch","year":"2011","unstructured":"Baitsch L, Baumgaertner P, Devevre E, Raghav SK, Legat A, Barba L, et al. Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. J Clin Invest. 2011;121(6):2350\u201360.","journal-title":"J Clin Invest"},{"issue":"17","key":"559_CR33","doi-asserted-by":"publisher","first-page":"7875","DOI":"10.1073\/pnas.1003345107","volume":"107","author":"J Matsuzaki","year":"2010","unstructured":"Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010;107(17):7875\u201380.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"559_CR34","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","volume":"72","author":"SR Woo","year":"2012","unstructured":"Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72(4):917\u201327.","journal-title":"Cancer Res"},{"issue":"17","key":"559_CR35","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1158\/1078-0432.CCR-15-0244","volume":"21","author":"JM Taube","year":"2015","unstructured":"Taube JM, Young GD, McMiller TL, Chen S, Salas JT, Pritchard TS, et al. Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade. Clin Cancer Res. 2015;21(17):3969\u201376.","journal-title":"Clin Cancer Res"},{"key":"559_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10501","volume":"7","author":"S Koyama","year":"2016","unstructured":"Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7:10501.","journal-title":"Nat Commun"},{"issue":"1","key":"559_CR37","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1249561","volume":"6","author":"RY Huang","year":"2017","unstructured":"Huang RY, Francois A, McGray AR, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology. 2017;6(1):e1249561.","journal-title":"Oncoimmunology"},{"issue":"9","key":"559_CR38","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3389\/fimmu.2018.00385","volume":"27","author":"FS Lichtenegger","year":"2018","unstructured":"Lichtenegger FS, Rothe M, Schnorfeil FM, Deiser K, Krupka C, Augsberger C, et al. Targeting LAG-3 and PD-1 to enhance T cell activation by antigen-presenting cells. Front Immunol. 2018;27(9):385.","journal-title":"Front Immunol"},{"issue":"4","key":"559_CR39","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","volume":"21","author":"CT Huang","year":"2004","unstructured":"Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004;21(4):503\u201313.","journal-title":"Immunity"},{"issue":"1","key":"559_CR40","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1006\/jmbi.1997.1116","volume":"270","author":"S Atwell","year":"1997","unstructured":"Atwell S, Ridgway JB, Wells JA, Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol. 1997;270(1):26\u201335.","journal-title":"J Mol Biol"},{"issue":"1","key":"559_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.virol.2009.09.012","volume":"395","author":"P Di Bonito","year":"2009","unstructured":"Di Bonito P, Grasso F, Mochi S, Petrone L, Fanales-Belasio E, Mei A, et al. Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein. Virology. 2009;395(1):45\u201355.","journal-title":"Virology"},{"issue":"5","key":"559_CR42","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.4049\/jimmunol.154.5.2257","volume":"154","author":"L Rivoltini","year":"1995","unstructured":"Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol. 1995;154(5):2257\u201365.","journal-title":"J Immunol"}],"container-title":["BMC Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-019-0559-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12896-019-0559-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-019-0559-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T20:05:30Z","timestamp":1695326730000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbiotechnol.biomedcentral.com\/articles\/10.1186\/s12896-019-0559-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,17]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["559"],"URL":"https:\/\/doi.org\/10.1186\/s12896-019-0559-x","relation":{},"ISSN":["1472-6750"],"issn-type":[{"type":"electronic","value":"1472-6750"}],"subject":[],"published":{"date-parts":[[2019,10,17]]},"assertion":[{"value":"20 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Human specimens used in some experiments described in our ms are PBMCs from healthy donors. Multiple stocks of human peripheral blood mononuclear cells (PBMCs) isolated from a large number of healthy donors (<i>n<\/i>\u00a0>\u200920), have been stored in liquid nitrogen in our laboratory. The PBMCs have been purified from buffy coats obtained from the Transfusion Center of the University of Rome \u201cLa Sapienza\u201d as waste material resulting from the procedures of plasma\/platelet\/red blood isolation from whole blood of healthy donors. They were volunteers and consented for their donated blood to be used for research. In line with the Italian law on this matter (Legislative Decree of the Italian Ministry of Health of January 25, 2001, published on the Official Gazette of April 3, 2001) donor ages ranged between 21 and 60\u2009years for women and 21\u201365\u2009years for men. There have been no restrictions for blood donors as to sex and ethnic background, except for children, mentally disabled individuals and pregnant women. All donors were healthy, non-medicated consulting adults, and were prescreened for exposure to infectious agents. Blood was obtained by venipuncture following standard medical procedures using sterile technique and a compression bandage in the area of blood removal. A record of the donor and hematocrit result is stored on file at the Transfusion Center. Research investigators do not have any access to personal data or other information concerning the donors in agreement with the Italian law Number 675 of December 31, 1996.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Alessandro Ascione (AA), Michela Flego (MFL), Alessandra Mallano (AM), Stefano Vella (SV) and Maurizio Federico (MFE) are co-inventors of a patent recently filed, regarding the human monoclonal antibody against LAG3 described in the present manuscript (Date of patent filing: 12\/07\/2019. Title: Human recombinant antibody against LAG3 membrane receptor, medical and diagnostic uses thereof).Apart from that the authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}